Timolol 0,5%/ dorzolamide 2% fixed combination 
versus timolol 0,5%/ pilocarpine 2% 
fixed combination in primary 
open-angle glaucoma or ocular 
hypertensive patients

Jakub Kałużny; Jerzy Szaflik; Krystyna Czechowicz-Janicka; Józef Kałużny; Ali­cja Orzał­kie­wi­cz; Anna Zaleska-Żmijewska; Małgorzata Krajewska; Je­anet­te Stewar; Jes­si­ca Leech; Wi­liam Stewar

Abstract

1-2/2004 vol. 106

Original paper

Timolol 0,5%/ dorzolamide 2% fixed combination versus timolol 0,5%/ pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients

Jakub J. Kałużny ¹

,

Jerzy Szaflik ²

,

Krystyna Czechowicz-Janicka ³

,

Józef Kałużny ¹

,

Alicja Orzałkiewicz ¹

,

Anna Zaleska-Żmijewska ²

,

Małgorzata Krajewska ³

,

Jeanette A. Stewar ⁴

,

Jessica N. Leech ⁴

,

Wiliam C. Stewar ^{4, 5}

Z Kliniki Okulistyki Akademii Medycznej im. Ludwika Rydygiera w Bydgoszczy
Z Samodzielnego Publicznego Klinicznego Szpitala Okulistycznego w Warszawie
Z Centrum Medycznego Kształcenia Podyplomowego w Warszawie
Pharmaceutical Research Network, Limited Liability Company, Charleston, South Carolina, USA
Department of Ophthalmology, University of South Carolina, Columbia, South Carolina, USA

KLINIKA OCZNA 2004, Supl. 1-2: S241–S242

Online publish date: 2022/12/30

View full text

AMA

Kałużny JJ, Szaflik J, Czechowicz-Janicka K, et al. Timolol 0,5%/ dorzolamide 2% fixed combination versus timolol 0,5%/ pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients. Klinika Oczna / Acta Ophthalmologica Polonica Supplement. 2004:241-242.

APA

Kałużny, J. J., Szaflik, J., Czechowicz-Janicka, K., Kałużny, J., Orzałkiewicz, A., & Zaleska-Żmijewska, A. et al. (2004). Timolol 0,5%/ dorzolamide 2% fixed combination versus timolol 0,5%/ pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients. Klinika Oczna / Acta Ophthalmologica Polonica Supplement, 241-242.

Chicago

Kałużny, Jakub J, Jerzy Szaflik, Krystyna Czechowicz-Janicka, Józef Kałużny, Alicja Orzałkiewicz, Anna Zaleska-Żmijewska, and Małgorzata Krajewska et al. 2004. "Timolol 0,5%/ dorzolamide 2% fixed combination versus timolol 0,5%/ pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients". Klinika Oczna / Acta Ophthalmologica Polonica Supplement: 241-242.

Harvard

Kałużny, J., Szaflik, J., Czechowicz-Janicka, K., Kałużny, J., Orzałkiewicz, A., Zaleska-Żmijewska, A., Krajewska, M., Stewar, J., Leech, J., and Stewar, W. (2004). Timolol 0,5%/ dorzolamide 2% fixed combination versus timolol 0,5%/ pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients. Klinika Oczna / Acta Ophthalmologica Polonica Supplement, pp.241-242.

MLA

Kałużny, Jakub et al. "Timolol 0,5%/ dorzolamide 2% fixed combination versus timolol 0,5%/ pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients." Klinika Oczna / Acta Ophthalmologica Polonica Supplement, 2004, pp. 241-242.

Vancouver

Kałużny J, Szaflik J, Czechowicz-Janicka K, Kałużny J, Orzałkiewicz A, Zaleska-Żmijewska A et al. Timolol 0,5%/ dorzolamide 2% fixed combination versus timolol 0,5%/ pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients. Klinika Oczna / Acta Ophthalmologica Polonica Supplement. 2004:241-242.

Purpose

To establish the efficacy and safety of timolol 0,5% / dorzolamide 2% fixed combination versus timolol 0,5% / pilocarpine 2% fixed combination, each given twice daily, in primary open-angle glaucoma and ocular hypertensive patients.

Material and methods

In this prospective, multicentred, double-masked trial, 37 patients were treated twice daily with timolol for 4 weeks. Then, they were randomized to one of the treatment medications for 6 weeks, after which they were treated with timolol again for 2 weeks before placed on the opposite treatment medication for 6 weeks.

Results

A total of 36 patients completed the trial. The mean baseline intraocular pressure (IOP) was 22,3± 3,7 mmHg. Following 6 weeks of treatment, the mean decrease of IOP was 18,0± 2,2 mmHg for timolol / dorzolamide combination and 17,4± 2,0 for timolol / pilocarpine combination. The mean diurnal curve IOP was 18,1± 2,2 mmHg for timolol / dorzolamide group and 16,7 ± 1,9 mmHg for timolol / pilocarpine group. These differences were statistically significant. Statistically more patients reported ocular pain and diminished vision during use of the timolol / pilocarpine combination.

Conclusions

This study suggest that timolol 0,5% / pilocarpine 2% fixed combination can provide at least similar efficacious reduction in IOP as timolol 0,5 % / dorzolamide 2% fixed combination in patients with primary open-angle glaucoma and ocular hypertension.

Keywords

open angle glaucoma, timolol, dorzolamide, pilokarpine